You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Article info

Article menu

Download PDFPDF

XML
Research Article
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Authors

  • Mariaelena Capone Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Diana Giannarelli Statistical Unit, Regina Elena National Cancer Institute Rome Italy PubMed articlesGoogle scholar articles
  • Domenico Mallardo Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Gabriele Madonna Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Lucia Festino Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Antonio Maria Grimaldi Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Vito Vanella Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Ester Simeone Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Miriam Paone Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  • Giuseppe Palmieri Unit of Cancer Genetics, Institute of Biomolecular Chemistry, CNR I-07100 Sassari Italy PubMed articlesGoogle scholar articles
  • Ernesta Cavalcanti Department of Diagnostic Pathology and LaboratoryIstituto Nazionale Tumori- IRCCS –Fondazione G. Pascale Napoli Italy PubMed articlesGoogle scholar articles
  • Corrado Caracò Melanoma and Skin Cancers Surgery UnitIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Napoli Italy PubMed articlesGoogle scholar articles
  • Paolo Antonio Ascierto Unit of Melanoma, Cancer Immunotherapy and Development TherapeuticsIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy PubMed articlesGoogle scholar articles
  1. ↵a marilenacapone{at}gmail.com
  2. ↵b diana.giannarelli{at}ifo.gov.it
  3. ↵c dome.mallardo{at}gmail.com
  4. ↵d gabriele.madonna{at}yahoo.it
  5. ↵e luciafestino1984.lf{at}gmail.com
  6. ↵f dott.a.m.grimaldi{at}gmail.com
  7. ↵g vitovanella1{at}gmail.com
  8. ↵h ester.simeone{at}gmail.com
  9. ↵i miriam.paone{at}gmail.com
  10. ↵j gpalmieri{at}yahoo.com
  11. ↵k e.cavalcanti{at}istitutotumori.na.it
  12. ↵l corrado.caraco{at}istitutotumori.na.it
  13. ↵m +39 081 5903236 p.ascierto{at}istitutotumori.na.it paolo.ascierto{at}gmail.com
View Full Text

Citation

Capone M, Giannarelli D, Mallardo D, et al
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Journal for ImmunoTherapy of Cancer 2018;6:74. doi: 10.1186/s40425-018-0383-1

Publication history

  • Received March 29, 2018
  • Accepted June 27, 2018
  • First published July 16, 2018.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.